Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CogstateASX:CGS -2.95%74 3-Year EBITDA Growth Rate is 12.40% as of Dec. 2025, which is 51% below its 10-year median of 25.10. GuruFocus rates ASX:CGS with a GF Score™ of 74/100 and a GF Value™ of A$2.10 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 525 Healthcare Providers & Services companies, Cogstate ranks better than 54.1% on this metric.
During the past 12 months, Cogstate's average EBITDA Per Share Growth Rate was 28.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 12.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 105.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cogstate was 263.40% per year. The lowest was -81.70% per year. And the median was 25.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cogstate 3-Year EBITDA Growth Rate Related Terms
ASX:CGS vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Cogstate's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogstate 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cogstate's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 12.40% mean?
Cogstate (ASX:CGS) has a 3-Year EBITDA Growth Rate of 12.40% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cogstate and its competitors. This is 51% below median its historical median of 25.10. According to the industry distribution chart, Cogstate ranks #241 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 45.9%.
Is Cogstate's 3-Year EBITDA Growth Rate too high?
Cogstate's current 3-Year EBITDA Growth Rate of 12.40% is 51% below median its 10-year median of 25.10. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Cogstate's value of 12.40% is 21.6% above this industry median. Based on the distribution chart, Cogstate ranks #241 out of 525 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Cogstate has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #241 out of 525 companies for 3-Year EBITDA Growth Rate. This puts Cogstate in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Cogstate's value of 12.40% is 21.6% above this benchmark. While the company's 10-year median is 25.10 vs. the industry median of 10.20, Cogstate has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogstate's current 3-Year EBITDA Growth Rate of 12.40% is 21.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cogstate and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogstate's current 3-Year EBITDA Growth Rate is 12.40%, which is 51% below median its own 10-year median of 25.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (ASX:CGS) is currently considered Modestly Overvalued. The stock's GF Value™ is A$2.10, compared to a current price of A$2.63 — trading 25.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 12.40%, which is 51% below median its 10-year median of 25.10 and 21.6% above the Healthcare Providers & Services industry median of 10.20. Cogstate's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cogstate (ASX:CGS), the current 3-Year EBITDA Growth Rate is 12.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cogstate (ASX:CGS) Overvalued in 2026?
Based on GuruFocus' analysis, Cogstate stock appears to be overvalued.
The current stock price of A$2.63 is trading 25.2% above its estimated GF Value™ of A$2.10.
GuruFocus considers Cogstate to be Modestly Overvalued.
Key valuation signals for ASX:CGS:
3-Year EBITDA Growth Rate: 12.40% (51% below median its 10-year median of 25.10)
GF Value™: A$2.10 vs. price of A$2.63 (25.2% above fair value)
Industry Position: 21.6% above the Healthcare Providers & Services median (#241 of 525)
No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
74GF Score
Get the complete analysis for ASX:CGS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CGS has been successfully added to your 
